F. Zhou

A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma

J. Hou, L. Qiu, Wenming Chen, 2017, American journal of clinical oncology.

High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial

Hong-guo Zhao, Xin Wang, M. Hou, 2020, American journal of hematology.

High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial.

M. Hou, Xue-bin Ji, Yawen Wang, 2016, Blood.

A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.

Hong-guo Zhao, Xin Wang, M. Hou, 2015, Blood.

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

Yan Liu, Hua Jiang, B. Jiang, 2017, Cancer Chemotherapy and Pharmacology.

Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients

J. Hou, X. Ke, L. Qiu, 2012 .

Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis

He Huang, Jiong Hu, Xiao-jun Huang, 2022, American journal of hematology.

Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)

Chuan Jin, Zhi-gang Peng, Xiao-hong Zhang, 2023, Cancer Immunology, Immunotherapy.